Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Investig Allergol Clin Immunol ; 15(3): 177-82, 2005.
Article in English | MEDLINE | ID: mdl-16261953

ABSTRACT

Primary immunodeficiency disorders include a variety of diseases that render patients more susceptible to infections. To determine the percentage of different primary immunodeficiency disorders diagnosed in the Children's Medical Center Hospital affiliated to Tehran University of Medical Sciences in Iran, we retrospectively reviewed the charts of the patients being referred to our hospital for immunologic evaluation of recurrent infections during a 20 year period. Among these patients, antibody deficiencies were the most frequent ones and were found in 52.6% of patients (n = 130). T-cell disorders, phagocytic disorders and complement deficiencies were found to be present in 24.69% (n = 61). 22.2% (n = 55) and 0.4% (n = 1) respectively. On the whole, common variable immunodeficiency was the most frequent disorder (n = 65), followed by ataxia telangiectasia (n = 39), X-linked agammaglobulinemia (n = 33), chronic granulomatous disease (n = 29) and selective IgA deficiency (n = 20). This study reveals that antibody deficiencies are the most common type of disorders as shown in other studies. A comparative study shows some differences between our results and other registries. This article also indicates that immunodeficiency disorders should be considered in patients with recurrent infections.


Subject(s)
Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/epidemiology , Adolescent , Adult , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Immunologic Deficiency Syndromes/classification , Immunologic Deficiency Syndromes/genetics , Infant , Iran/epidemiology , Male , Phenotype , Retrospective Studies
2.
Immunol Invest ; 32(4): 313-21, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14603997

ABSTRACT

Primary complement deficiencies are rare and two related patients are reported here. The first patient is a 41-year-old man with eighteen episodes of pneumococcal meningitis and other purulent infections. The serum C3 level was checked at three separate times, showing that this was a primary C3 deficient case; other immunological tests were normal. This patient now takes prophylactic antibiotics and the meningitis had not recurred, but he does have glomerulonephritis. The second case is a 40-year-old woman with repeated episodes of orofacial and laryngeal edema and dyspnea. The serum C1INH levels were 4.3 to 7 which is very low compared with normal healthy subjects (C1INH was 40-50 mg/dl) and C4 was lower than normal but other immunological tests were normal. Other causes of angioedema such as lymphoproliferative disorders were excluded. She had hereditary angioedema without a family background. The condition may be due to genetic mutation. The angioedema was controlled with Danazol and Stanasol. As our patients are related, this may suggest a genetic relationship between these two disorders.


Subject(s)
Complement C3/deficiency , Adult , Anti-Bacterial Agents/therapeutic use , Danazol/therapeutic use , Dyspnea/complications , Edema/complications , Edema/drug therapy , Female , Genetic Diseases, Inborn/blood , Genetic Diseases, Inborn/complications , Genetic Diseases, Inborn/genetics , Glomerulonephritis/complications , Humans , Male , Meningitis, Pneumococcal/complications , Meningitis, Pneumococcal/drug therapy , Pedigree , Stanozolol/therapeutic use
4.
Curr Opin Clin Nutr Metab Care ; 3(5): 355-62, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11151079

ABSTRACT

The amino acid glutamine has become one of the most intensively studied nutrients in the field of nutrition and metabolic support. A variety of studies in cell culture systems, animal models of gut mucosal atrophy, injury/repair and adaptation and a limited number of clinical trials demonstrate trophic and cytoprotective effects of glutamine in small bowel and colonic mucosal cells. Although the routine clinical use of glutamine-enriched parenteral and enteral nutrient solutions remains controversial, available data demonstrate both the safety and metabolic and clinical efficacy of glutamine treatment in selected patient groups. Basic investigations are elucidating underlying mechanisms of glutamine action in intestinal cells. These will inform preclinical and clinical investigations designed to determine glutamine efficacy in selected gastrointestinal disorders. Emerging clinical trials will further define the utility of adjunctive glutamine supplementation as a component of specialized nutrition support in gastrointestinal disease.


Subject(s)
Digestive System/drug effects , Glutamine/pharmacology , Nutritional Support , Adaptation, Biological , Animals , Cells, Cultured , Clinical Trials as Topic , Dietary Supplements , Glutamine/metabolism , Humans , Intestinal Absorption , Models, Animal
SELECTION OF CITATIONS
SEARCH DETAIL
...